Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor

EDP-239, a potent and selective hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor developed for the treatment of HCV infection, has been investigated in vitro and in vivo. This study sought to characterize genotypic changes in the HCV NS5A sequence of genotype 1 (GT1) replicons and t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Owens, Christopher M., Brasher, Bradley B., Polemeropoulos, Alex, Rhodin, Michael H. J., McAllister, Nicole, Wong, Kelly A., Jones, Christopher T., Jiang, Lijuan, Lin, Kai, Or, Yat Sun
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2016
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038316/
https://ncbi.nlm.nih.gov/pubmed/27503644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00815-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados